Microbot Medical (NASDAQ:MBOT) Coverage Initiated by Analysts at B. Riley Securities

B. Riley Securities assumed coverage on shares of Microbot Medical (NASDAQ:MBOT) in a report published on Tuesday, MarketBeat reports. The brokerage issued a buy rating and a $5.00 price target on the biotechnology company’s stock.

MBOT has been the subject of several other research reports. Roth Mkm began coverage on Microbot Medical in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $5.50 target price for the company. Wall Street Zen cut Microbot Medical from a “hold” rating to a “sell” rating in a research note on Saturday, October 25th. HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Microbot Medical in a research report on Friday, November 28th. Finally, B. Riley Financial started coverage on shares of Microbot Medical in a research report on Tuesday. They issued a “buy” rating on the stock. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $7.50.

Microbot Medical Trading Up 11.4%

Shares of NASDAQ MBOT opened at $2.05 on Tuesday. Microbot Medical has a 12 month low of $1.25 and a 12 month high of $4.67. The firm has a market capitalization of $137.67 million, a PE ratio of -4.56 and a beta of 1.28. The firm has a fifty day simple moving average of $2.09 and a two-hundred day simple moving average of $2.61.

Microbot Medical (NASDAQ:MBOT) last announced its earnings results on Wednesday, November 12th. The biotechnology company reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.01). On average, sell-side analysts predict that Microbot Medical will post -0.71 earnings per share for the current year.

Institutional Trading of Microbot Medical

Several institutional investors have recently bought and sold shares of MBOT. Cornerstone Advisory LLC bought a new stake in Microbot Medical during the 3rd quarter valued at about $30,000. Zacks Investment Management purchased a new stake in shares of Microbot Medical during the third quarter valued at approximately $33,000. Squarepoint Ops LLC bought a new stake in shares of Microbot Medical during the third quarter valued at approximately $37,000. Foundations Investment Advisors LLC bought a new stake in shares of Microbot Medical during the third quarter valued at approximately $38,000. Finally, SLT Holdings LLC purchased a new position in Microbot Medical in the 3rd quarter worth approximately $38,000. 16.30% of the stock is owned by hedge funds and other institutional investors.

About Microbot Medical

Microbot Medical Inc (NASDAQ: MBOT) is a medical device company focused on the design, development and commercialization of micro-robotic platforms for minimally invasive procedures. Leveraging proprietary microbot technology, the company aims to navigate complex vascular and luminal pathways within the body to deliver therapy, retrieve tissue samples or perform diagnostic tasks in a precise, targeted manner.

Microbot Medical operates two primary technology divisions. Its endovascular platform is designed to traverse blood vessels and deliver clot-retrieval systems, drug payloads or cell-based therapies directly at the site of vascular injury, with applications in acute ischemic stroke and peripheral artery disease.